<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37457286</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Post-acute (long) COVID-19 quality of life: validation of the German version of (PAC19QoL) instrument.</ArticleTitle><Pagination><StartPage>1163360</StartPage><MedlinePgn>1163360</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1163360</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2023.1163360</ELocationID><Abstract><AbstractText Label="PURPOSE">The aim of our study was to validate a German translation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument among German patients with long COVID-19 syndrome.</AbstractText><AbstractText Label="PATIENTS AND METHODS">The PAC-19QoL instrument was translated into the German language and administrated to patients with long COVID-19 syndrome. Cronbach's alpha coefficient was used to analyze the internal consistency of the instrument. Construction validity was evaluated by using Pearson's correlation coefficient and Spearman's rank correlation. Scores of patients and controls were compared using the Mann-Whitney <i>U</i>-test.</AbstractText><AbstractText Label="RESULTS">A total of 45 asymptomatic and 41 symptomatic participants were included. In total, 41 patients with long COVID-19 syndrome completed the PAC-19QoL and EQ-5D-5L questionnaires. PAC-19QoL domain scores were significantly different between symptomatic and asymptomatic participants. All items achieved a Cronbach's alpha &gt;0.7. There was a significant correlation between all domains on the test (<i>p</i> &lt; 0.001), with the highest correlation between total (<i>r</i> = 0.994) and domain 1 (<i>r</i> = 0.991). Spearman's rank correlation analysis confirmed that the instrument items correlated with the objective PAC-19QoL examination findings.</AbstractText><AbstractText Label="CONCLUSION">The German version of the instrument is valid and reliable and can be a suitable tool for research and daily clinical practice among patients with long COVID-19 syndrome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Umakanthan, Monice, Mehboob, Jones and Lawrence.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Umakanthan</LastName><ForeName>Srikanth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Para-Clinical Sciences, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monice</LastName><ForeName>Mariam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Independent Researcher, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehboob</LastName><ForeName>Salona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Independent Researcher, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Cheryl Linda</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Independent Researcher, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>COVID-19 Independent Research Study Group, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016441">Retracted Publication</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="RetractionIn"><RefSource>Front Public Health. 2023 Oct 31;11:1308285. doi: 10.3389/fpubh.2023.1308285</RefSource><PMID Version="1">38026381</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EQ-5D-5L</Keyword><Keyword MajorTopicYN="N">PAC-19QoL</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">questionnaire</Keyword><Keyword MajorTopicYN="N">validation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>18</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>4</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37457286</ArticleId><ArticleId IdType="pmc">PMC10349205</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2023.1163360</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . WHO Coronavirus Disease (COVID-19) Dashboard. Available online at: https://COVID19.who.int/ (accessed December 13, 2022).</Citation></Reference><Reference><Citation>World Health Organization . A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. Available online at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (accessed November 12, 2022).</Citation></Reference><Reference><Citation>Umakanthan S, Lawrence S. Predictors of COVID-19 vaccine hesitancy in Germany: a cross-sectional, population-based study. Postgrad Med J. (2022) 98:756&#x2013;64. 10.1136/postgradmedj-2021-141365</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-141365</ArticleId><ArticleId IdType="pubmed">37062994</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. (2022) 39:159&#x2013;67. 10.1093/fampra/cmab076</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G, Monaghan A, Xue F, Duggan E, Romero-Ortu&#xf1;o R. Comprehensive clinical characterisation of brain fog in adults reporting long COVID symptoms. J Clin Med. (2022) 11:3440. 10.3390/jcm11123440</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11123440</ArticleId><ArticleId IdType="pmc">PMC9224578</ArticleId><ArticleId IdType="pubmed">35743516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowery SA, Sariol A, Perlman S. Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19. Cell Host Microbe. (2021) 29:1052&#x2013;62. 10.1016/j.chom.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8126603</ArticleId><ArticleId IdType="pubmed">34022154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena A, Mishra S, Deepak P, Kumar-M P, Sharma A, Patel YI, et al. . Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. (2022) 21:102927. 10.1016/j.autrev.2021.102927</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102927</ArticleId><ArticleId IdType="pmc">PMC8404391</ArticleId><ArticleId IdType="pubmed">34474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. . Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. (2021) 26:107&#x2013;8. 10.1136/bmjebm-2020-111536</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjebm-2020-111536</ArticleId><ArticleId IdType="pmc">PMC7493072</ArticleId><ArticleId IdType="pubmed">32934000</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. (2020) 95:304&#x2013;7. 10.1016/j.ijid.2020.04.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.04.061</ArticleId><ArticleId IdType="pmc">PMC7194601</ArticleId><ArticleId IdType="pubmed">32344011</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N, et al. . Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial. Ann Intern Med. (2022) 175:1126&#x2013;34. 10.7326/M22-0729</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0729</ArticleId><ArticleId IdType="pmc">PMC9186515</ArticleId><ArticleId IdType="pubmed">35667065</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakoor H, Feehan J, Al Dhaheri AS, Ali HI, Platat C, Ismail LC, et al. . Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19?. Maturitas. (2021) 143:1&#x2013;9. 10.1016/j.maturitas.2020.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2020.08.003</ArticleId><ArticleId IdType="pmc">PMC7415215</ArticleId><ArticleId IdType="pubmed">33308613</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A, Squitti R, Picozza M, Pawar A, Rongioletti M, Dutta AK, et al. . Zinc and COVID-19: basis of current clinical trials. Biol Trace Elem Res. (2021) 199:2882&#x2013;92. 10.1007/s12011-020-02437-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-020-02437-9</ArticleId><ArticleId IdType="pmc">PMC7580816</ArticleId><ArticleId IdType="pubmed">33094446</ArticleId></ArticleIdList></Reference><Reference><Citation>EUROQOL . EQ-5D. Available online at: https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/ (accessed November 01, 2022).</Citation></Reference><Reference><Citation>Jandhyala R. Design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument. Health Qual Life Outcomes. (2021) 19:229. 10.21203/rs.3.rs-255825/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-255825/v1</ArticleId><ArticleId IdType="pmc">PMC8477362</ArticleId><ArticleId IdType="pubmed">34583690</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Group ftGAC-P-ACS. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Arab-Zozani M, Hashemi F, Safari H, Yousefi M, Ameri H. Health-related quality of life and its associated factors in COVID-19 patients. Osong Public Health Res Perspect. (2020) 11:296&#x2013;302 10.24171/j.phrp.2020.11.5.05</Citation><ArticleIdList><ArticleId IdType="doi">10.24171/j.phrp.2020.11.5.05</ArticleId><ArticleId IdType="pmc">PMC7577388</ArticleId><ArticleId IdType="pubmed">33117634</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. . Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. (2021) 93:1013&#x2013;22 10.1002/jmv.26368</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Valent A, Dudoignon E, Ressaire Q, D&#xe9;pret F, Plaud B. Three-month quality of life in survivors of ARDS due to COVID-19: a preliminary report from a French academic centre. Anaesth Crit Care Pain Med. (2020) 39:740&#x2013;1 10.1016/j.accpm.2020.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.accpm.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7547571</ArticleId><ArticleId IdType="pubmed">33049394</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Thirupath R, Pillai S, et al. . Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol. (2022) 94:253&#x2013;62. 10.1002/jmv.27309</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. . Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. (2020) 81: e4&#x2013;6. 10.1016/j.jinf.2020.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. (2021) 397:220&#x2013;32. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Parik PC, Patel VJ. Health-related quality of life of patients with type 2 diabetes mellitus at a tertiary care hospital in India using EQ 5D 5L. Indian J Endocrinol metab. (2019) 23:407&#x2013;11. 10.4103/ijem.IJEM_29_19</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijem.IJEM_29_19</ArticleId><ArticleId IdType="pmc">PMC6844180</ArticleId><ArticleId IdType="pubmed">31741897</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitosek-Szewczyk K, Ku&#x142;akowska A, Bartosik-Psujek H, Hozejowski R, Drozdowski W, Stelmasiak Z. Quality of life in polish patients with multiple sclerosis. Adv Med Sci. (2014) 59:34&#x2013;8. 10.1016/j.advms.2013.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2013.07.002</ArticleId><ArticleId IdType="pubmed">24797971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul&#xe8; G, et al. . Female sex is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. (2022) 28:611. 10.1016/j.cmi.2021.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, et al. . Risk factors associated with long COVID syndrome: a retrospective study. Iran J Med Sci. (2021) 46:428&#x2013;36. 10.30476/ijms.2021.92080.2326</Citation><ArticleIdList><ArticleId IdType="doi">10.30476/ijms.2021.92080.2326</ArticleId><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, Pelosi P, Rocco PRM. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Front Immunol. (2022) 13:857573. 10.3389/fimmu.2022.857573</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.857573</ArticleId><ArticleId IdType="pmc">PMC9091347</ArticleId><ArticleId IdType="pubmed">35572561</ArticleId></ArticleIdList></Reference><Reference><Citation>Haitao T, Vermunt JV, Abeykoon J, Ghamrawi R, Ghamrawi R, Jayachandran M, et al. . COVID-19 and sex differences: mechanisms and biomarkers. Mayo Clin Proc. (2020) 95:2189&#x2013;203. 10.1016/j.mayocp.2020.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7402208</ArticleId><ArticleId IdType="pubmed">33012349</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J. Researchers home in on COVID-19 severity biomarkers. JAMA. (2020) 324:128. 10.1001/jama.2020.11397</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.11397</ArticleId><ArticleId IdType="pubmed">32662846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes CS, Maes M, Roomruangwong C, Moraes JB, Bonifacio KL, Vargas HO, et al. . Lowered quality of life in mood disorders is associated with increased neuro-oxidative stress and basal thyroid-stimulating hormone levels and use of anticonvulsant mood stabilizers. J. Eval. Clin. Pract. 2018, 24, 869&#x2013;878. 10.1111/jep.12918</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jep.12918</ArticleId><ArticleId IdType="pubmed">29665163</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavicchioli F.L.; Maes, M.; Roomruangwong, C.; Bonifacio, K.L.; Barbosa, D.S.; Anderson, G.; Vargas, H.O.; Nunes, S.O.V. Associations between severity of anxiety and clinical and biological features of major affective disorders. Psychiatry Res. (2018) 260:17&#x2013;23. 10.1016/j.psychres.2017.11.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2017.11.024</ArticleId><ArticleId IdType="pubmed">29156296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanchanatawan B, Sriswasdi S, Maes M. Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia. Metab. Brain Dis. (2019) 34:267&#x2013;82. 10.1007/s11011-018-0339-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-018-0339-7</ArticleId><ArticleId IdType="pubmed">30467771</ArticleId></ArticleIdList></Reference><Reference><Citation>Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, et al. . Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. (2020) 96:753&#x2013;48. 10.1136/postgradmedj-2020-138234</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-138234</ArticleId><ArticleId IdType="pmc">PMC10016932</ArticleId><ArticleId IdType="pubmed">32563999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. A new schizophrenia model: immune activation is associated with the induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions. CNS Neurol. Disord. Drug Targets. (2019) 18:124&#x2013;40. 10.2174/1871527317666181119115532</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527317666181119115532</ArticleId><ArticleId IdType="pubmed">30451122</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Moraes JB, Congio A, Bonifacio KL, Barbosa DS, Vargas HO, et al. . Development of a novel staging model for affective disorders using partial least squares bootstrapping: effects of lipid-associated antioxidant defenses and neuro-oxidative stress. Mol. Neurobiol. (2019) 56:6626&#x2013;44. 10.1007/s12035-019-1552-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1552-z</ArticleId><ArticleId IdType="pubmed">30911933</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Moraes JB, Bonifacio KL, Barbosa DS, Vargas HO, Michelin AP, et al. . Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach. Metab Brain Dis. (2021) 36:509&#x2013;21. 10.1007/s11011-020-00656-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-020-00656-6</ArticleId><ArticleId IdType="pubmed">33411213</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Kubera M, Stoyanova K, Leunis JC. The reification of the clinical diagnosis of myalgic encephalomyelitis/ chronic fatigue syndrome (me/cfs) as an immune and oxidative stress disorder: construction of a data-driven nomothethic network and exposure of ME/CFS subgroups. Curr Top Med Chem. (2021) 21:1488&#x2013;99. 10.2174/1568026621666210727170147</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026621666210727170147</ArticleId><ArticleId IdType="pubmed">34315375</ArticleId></ArticleIdList></Reference><Reference><Citation>Umakanthan S, Bukelo MM, Gajula SS. The commonwealth Caribbean COVID-19: Regions resilient pathway during pandemic. Front Public Health. (2022) 10:844333. 10.3389/fpubh.2022.844333</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.844333</ArticleId><ArticleId IdType="pmc">PMC9160791</ArticleId><ArticleId IdType="pubmed">35664108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousa RF, Smesam HN, Qazmooz HA, Al-Hakeim HK, Maes M. A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina. CNS Spectr. (2021) 27:1&#x2013;15. 10.1017/S1092852921000432</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1092852921000432</ArticleId><ArticleId IdType="pubmed">34039448</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim HK, Hadi HH, Jawad GA, Maes M. Intersections between copper, &#x3b2;-arrestin-1, calcium, FBXW7, CD17, insulin resistance and atherogenicity mediate depression and anxiety due to type 2 diabetes mellitus: a nomothetic network approach. J Pers Med. (2022) 12:23. 10.3390/jpm12010023</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12010023</ArticleId><ArticleId IdType="pmc">PMC8779500</ArticleId><ArticleId IdType="pubmed">35055338</ArticleId></ArticleIdList></Reference><Reference><Citation>Faro M, S&#xe0;ez-Franc&#xe1;s N, Castro-Marrero J, Aliste L, Fern&#xe1;ndez de Sevilla T, Alegre J. Sex differences in chronic fatigue syndrome. Reumatol Clin. (2016) 12:72&#x2013;7. 10.1016/j.reumae.2015.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reumae.2015.05.009</ArticleId><ArticleId IdType="pubmed">26190206</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry. (2006) 51:100&#x2013;13. 10.1177/070674370605100206</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/070674370605100206</ArticleId><ArticleId IdType="pubmed">16989109</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Al-Rubaye HT, Almulla AF, Al-Hadrawi DS, Stoyanova K, Kubera M, et al. . Lowered quality of life in long COVID is predicted by affective symptoms, chronic fatigue syndrome, inflammation and neuroimmunotoxic pathways. Int J Environ Res Public Health. (2022) 19:10362. 10.3390/ijerph191610362</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191610362</ArticleId><ArticleId IdType="pmc">PMC9408685</ArticleId><ArticleId IdType="pubmed">36011997</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble RE. Depression in women. Metabolism. (2005) 54(Suppl. S1):49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15877314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>